Decoding the Future of K-Bio Value
Navigating the Quantum Leap of K-Bio
-
K-Bio Industry Overview: 2025 Performance and 2026 Outlook In 2025, the K-Bio industry demonstrated solid growth, driven by expanding global demand for biopharmaceuticals and the strengthening competitiveness of Korean biotech companies. Exports of biopharmaceutical products increased steadily, supported by large-scale biologics manufacturing, growing biosimilar penetration, and continued progress in innovative…
-
“Beyond RNA 1.0 (Silencing) to RNA 2.0 (Replacement)” Rznomics’ core value lies in its world-first RNA Trans-splicing Ribozyme platform. While traditional RNAi technologies (like siRNA) focus on “cutting and destroying” harmful mRNA, Rznomics focuses on “reprogramming” it. 1. Core Platform: RNA Trans-splicing Ribozyme This technology utilizes a “molecular pair of…
● Latest Articles
-
“지금 사도 될까?” 알테오젠, 기술적 독점력을 위협하는 차세대 기술의 등장
현 알테오젠 시총 적절한가?
-
Alteogen
Alteogen is evolving from a platform provider into a global biopharmaceutical powerhouse. Its strategy is anchored by the Hybrozyme (ALT-B4) platform, which is currently the…
-
OliX Pharmaceuticals
OliX Pharmaceuticals is moving beyond the liver to own the “non-liver” RNAi delivery platforms of the future. Its strategy is focused on cp-asiRNA for local…
-
Chong Kun Dang (CKD)
Technical Analysis: The Power of Open Innovation & Commercialization Chong Kun Dang has solidified its position by expertly blending proprietary drug development with strategic in-licensing…
● About Me
“PhD Scientist & 10-Year K-Bio Investor: Decoding the Life Science of Value.”
I am a Life Sciences PhD with industrial R&D experience across mAbs, BsAbs, ADCs, Vaccines, Cell/Gene Therapy and Medical Devices. By merging my technical expertise with over a decade of active investment in the K-Bio market, I translate complex innovation into clear, data-driven insights to help you find the real value behind the jargon.
K-Bio Value Report 